Arthneeti

Ajooni Biotech Q2 FY27 Share Price & Earnings Call Analysis

₹3.13+9.06% today
Market cap
₹57 Cr
P/E
14.33
ROE
4.28%
PEG
0.28
Price to sales
0.26
Debt to equity
0.19
52W high / low
₹6.01 / ₹2.83
Sales growth (5Y)
29.02%
EBITDA margin
3.36%
Net profit margin
2.11%
Promoter holding
30.53%
Sales (last year)
₹215 Cr

Incorporated in 2010, Ajooni Biotech Ltd is a PURE VEG. animal health care solutions company. It is a significant player in the animal feed and aquaculture sectors.[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Food Products
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Ajooni Biotech rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Food Products companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹439 Cr7.5
240%+Flat₹23,053 Cr132.2
340%+Flat₹1,035 Cr44.8
440%+Flat₹145 Cr9.7
520–40%Up 2%+₹683 Cr49.2
620–40%Up 2%+₹271 Cr8.0

Sign up free to see every company in the sector ranking and track Ajooni Biotech.

Pro shows every company guiding 40%+ revenue growth →Full Food Products ranking

Financials of Ajooni Biotech

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Ajooni Biotech

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +26.44%26.44%26.89%26.89%26.89%26.89%26.89%26.89%26.89%26.89%26.89%30.53%
FIIs +0.00%0.00%0.00%0.29%0.18%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public +73.56%73.56%73.11%72.82%72.92%73.11%73.11%73.11%73.11%73.11%73.11%69.47%
No. of Shareholders30,93341,05351,22463,90664,10263,96863,30564,30562,69961,77960,67559,633

Financials of Ajooni Biotech

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +19.4820.0519.5825.6625.7234.0329.2731.2731.7458.7560.6263.4965.37
YoY Sales growth+89.31%+88.62%-52.54%+22.19%+32.03%+69.73%+49.49%+21.86%+23.41%+72.64%+107.11%+103.04%+105.95%
Expenses +18.8520.7017.9924.7024.9533.1028.2630.5630.2455.7259.6161.8263.35
Operating Profit0.63-0.651.590.960.770.931.010.711.503.031.011.672.02
OPM %3.23%-3.24%8.12%3.74%2.99%2.73%3.45%2.27%4.73%5.16%1.67%2.63%3.09%
Other Income +0.291.570.260.040.310.391.340.650.150.321.300.270.32
Interest0.190.120.110.150.060.070.060.080.170.180.290.480.71
Depreciation0.210.210.240.220.230.240.380.250.250.810.900.800.92
Profit before tax0.520.591.500.630.791.011.911.031.232.361.120.660.71
Tax %23.08%23.73%38.67%25.40%22.78%27.72%19.37%24.27%24.39%30.08%15.18%34.85%28.17%
Net Profit +0.400.440.910.470.620.731.540.780.931.650.950.430.51
EPS in Rs0.040.040.090.030.040.040.090.050.050.100.060.020.03

Financials of Ajooni Biotech

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +7132942404051747480115182248
Sales growth+1,165%+84%+116%+48%-6%+1%+27%+46%+1%+7%+43%+59%+97%
Expenses +7132841393949717278111175240
Operating Profit0011112332468
OPM %1.8%1.7%2.4%2.2%1.7%3.1%3.2%4.2%3.7%2.8%3.2%3.4%3.1%
Other Income +0000000002222
Interest0000001101012
Depreciation0000001111123
Profit before tax0000000123465
Tax %27%29%28%20%15%29%26%28%28%28%22%25%
Net Profit +0000000112344
EPS in Rs0.150.210.360.090.090.060.060.160.110.220.200.250.21
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Ajooni Biotech

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital0.240.240.3366810101818343436
Reserves001567662425545758
Borrowings +011555755221833
Other Liabilities +1111412671235116
Total Liabilities22131918232829594895120132
Fixed Assets +00111256610112633
CWIP0000000001000
Investments0066431142323
Other Assets +12612131822224834809297
Total Assets22131918232829594895120132

Financials of Ajooni Biotech

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +0-1-3-3-5-414-623-32-6
Cash from Investing Activity +-0-0-2-010-3-2-16814-16
Cash from Financing Activity +0158-132-222-42515
Net Cash Flow0-005-5-10-00276-6
Free Cash Flow-0-1-3-3-5-6-22-817-33-23
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit169%-257%-427%-284%-706%-353%71%125%-185%1,047%-845%-92%

Financials of Ajooni Biotech

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days40331725441159868101595236
Inventory Days221463195134463439809097
Days Payable6627799122046395681322
Cash Conversion Cycle-42013584129986383131129111
Working Capital Days59-29-18410577589413215893
ROCE %28%18%37%10%4%4%5%9%6%8%5%6%

Continue your research

What Ajooni Biotech's management said in earlier quarters

Others in Food Products this season

  • EID Parry (Q2 FY27)

    Sugar Segment Q2 FY27 revenue: ₹486 Cr, up 32% from ₹368 Cr in Q2 FY26; sales volume increased from 118.8k MT to 172.2k MT. Key results statement takeaways from

  • The Bombay Burmah (Q2 FY27)

    Revenue from operations (consolidated) for the quarter ended 30 September 2026: ₹5,797.81 crores (Page 15). Key results statement takeaways from The Bombay Burm

  • Venky's (India) (Q2 FY27)

    31.7% increase . Key results statement takeaways from Venkys (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Apex Frozen Food (Q2 FY27)

    Q2FY27 Net Revenue: Rs 2,737 Mn, up 15% YoY from Rs 2,383 Mn in Q2FY26. Key investor presentation takeaways from Apex Frozen Foods Ltd's Q2 FY27 investor presen